No Data
No Data
VIRX Granted US Patent #12012396 For "HDAC Inhibitor Solid State Forms (For The Treatment Of Cancer, Immune Disorders)"
VIRX Granted US Patent #12012396 For "HDAC Inhibitor Solid State Forms (For The Treatment Of Cancer, Immune Disorders)"
Express News | XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (Prv) For $108MTo An Undisclosed Buyer
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersViracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock in
Oppenheimer Maintains Viracta Therapeutics(VIRX.US) With Buy Rating, Cuts Target Price to $11
Oppenheimer analyst Hartaj Singh maintains $Viracta Therapeutics(VIRX.US)$ with a buy rating, and adjusts the target price from $13 to $11.According to TipRanks data, the analyst has a success rate of
Express News | Viracta Therapeutics Inc : Oppenheimer Cuts Target Price to $11 From $13
Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
No Data